Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Reference Guide
  /  
ABCA1
Sign up free to test for 
ABCA1
.
One login for 30+ lab companies.

ABCA1

ABCA1 is a gene; genes code for proteins. The protein made by this gene is part of a group of proteins called ATP-binding cassette (ABC) transporters, which help move different molecules across cell membranes.

This specific protein belongs to the ABC1 subfamily, which is found only in multicellular organisms. It acts as a pump to remove cholesterol from cells as part of the cellular lipid removal process. 

Mutations in both copies of this gene cause Tangier disease and familial high-density lipoprotein (HDL) deficiency, conditions affecting cholesterol levels.

The ABCA1 Gene in Cholesterol Metabolism and Lipid Transport

The ABCA1 gene plays a crucial role in cholesterol metabolism and lipid transport within the body. Specifically, it functions as an efflux pump responsible for removing excess cholesterol from cells, facilitating the formation of high-density lipoprotein (HDL) particles essential for cholesterol transport in the bloodstream. 

Dysfunction or mutations in the ABCA1 gene can lead to impaired cholesterol efflux from cells; this causes excessive cholesterol buildup in the tissues and cells.

Understanding ABCA1-related conditions

Dysfunction or mutations in the ABCA1 gene can lead to impaired cholesterol efflux, contributing to conditions such as Tangier disease and familial high-density lipoprotein (HDL) deficiency.

Tangier Disease

Tangier disease, also known as familial alpha-lipoprotein deficiency, is an exceptionally rare genetic disorder characterized by extremely low levels of high-density lipoprotein (HDL) cholesterol in the blood. This condition results from homozygous mutations in the ABCA1 gene, impairing the ability of cells to remove cholesterol and leading to the accumulation of cholesterol-laden cells throughout the body.  [2.]

Symptoms of Tangier disease can vary widely but may include enlarged tonsils and lymph nodes, hepatosplenomegaly, peripheral neuropathy, and an increased risk of cardiovascular disease. Tangier disease is exceptionally rare, with only a few hundred cases reported worldwide.

Familial High-Density Lipoprotein (HDL) Deficiency

Familial high-density lipoprotein (HDL) deficiency is a genetic disorder characterized by abnormally low levels of HDL cholesterol in the blood. This condition increases the risk of cardiovascular disease due to impaired cholesterol transport and metabolism. 

Clinical manifestations of familial HDL deficiency may include premature coronary artery disease, atherosclerosis, and lipid deposits in various tissues. 

Genetic factors, particularly mutations in genes such as ABCA1 and APOA1, play a significant role in the development of this disorder, disrupting the synthesis, metabolism, or transport of HDL particles within the body. 

Early detection and management of familial HDL deficiency are crucial for reducing the risk of cardiovascular complications and improving overall health outcomes.  [4.]

What Else Can Happen if ABCA1 Does Not Function?

In addition to Tangier disease and familial high-density lipoprotein (HDL) deficiency, mutations in the ABCA1 gene have been associated with other conditions affecting lipid metabolism and cardiovascular health. 

For example, heterozygous mutation of the ABCA1 gene is associated with familial/primary hypoalphalipoproteinemia, a disorder characterized by low levels of HDL cholesterol.  

ABCA1 mutations may have implications for various manifestations of cardiovascular disease including the development of atherosclerosis, coronary artery disease, and other cardiovascular complications. 

ABCA1 mutations may also promote impaired glucose metabolism: by allowing cholesterol to build up inside the pancreas, pancreatic beta cell function slows and insulin production is impaired.  [3.]

Understanding the role of ABCA1 mutations in these conditions is essential for accurate diagnosis, risk assessment, and the development of targeted treatment strategies aimed at improving lipid profiles and reducing the risk of cardiovascular events.  [4.]

Diagnostic Testing for ABCA1-Related Disorders

Screening and diagnostic methods for identifying ABCA1 mutations

Appropriate screening for ABCA1 mutations involves genetic testing, which can be conducted through targeted sequencing or comprehensive gene panels. Screening is recommended for individuals with a family history of lipid disorders, premature cardiovascular disease, or suspected Tangier disease or familial HDL deficiency. 

Those who test positive for ABCA1 mutations should have additional cardiovascular screening including blood sugar screening.  [3.]

Genetic counseling should accompany screening to discuss potential implications of identified mutations and provide guidance on appropriate management and preventive measures.

Importance of genetic counseling and family screening

Genetic counseling plays a crucial role in helping individuals decide whether to screen for ABCA1 mutations, as it provides individuals and families with essential information about the implications of genetic test results. 

Specifically, it helps individuals understand recommended followup to assess their risk of developing lipid disorders and cardiovascular disease based on identified mutations. 

Additionally, family screening is vital for identifying at-risk relatives, facilitating early detection, and implementing preventive measures to mitigate the impact of ABCA1-related conditions across generations.

Management and treatment strategies

General recommendations for management and treatment strategies for individuals with ABCA1 gene mutations include lifestyle modifications to promote heart health, such as maintaining a healthy diet, regular exercise, and avoiding tobacco use, along with pharmacological interventions aimed at managing lipid levels and reducing cardiovascular risk.

Individuals with homozygous mutations for the ABCA1 gene may be referred to genetic counseling and/or additional specialists for personalized care.  

Lifestyle modifications for managing cholesterol levels

Lifestyle modifications for cholesterol health and reducing cardiovascular disease risk include adopting a balanced diet rich in fruits, vegetables, whole grains, and healthy fats, engaging in regular physical activity, maintaining a healthy weight, and avoiding smoking and excessive alcohol consumption.

Studies have found the Mediterranean diet and the Portfolio diets to be helpful in managing cholesterol levels.  [5.]  Other studies have reported beneficial effects in raising HDL levels on a low carbohydrate/low sugar diet, and/or a diet including soy.  [9.]

Exercise, including aerobic and resistance training exercises, have been shown to raise HDL levels.  [6., 7.]

Pharmacological interventions for ABCA1-related disorders

In patients with low HDL levels only, most treatment guidelines do not recommend medications specifically to increase HDL levels.  

Pharmacological management for ABCA1-related cardiovascular disease may include lipid-lowering medications such as statins, fibrates, and niacin to control cholesterol levels and reduce the risk of cardiovascular complications. 

Potential Future Therapies and Research Advancements

Novel therapies targeting specific pathways involved in lipid metabolism are under investigation as potential treatment options for these rare genetic conditions.

Patient Education and Support

Resources for patients and families affected by ABCA1-related conditions

Importance of Regular Monitoring and Follow-up Care

Regular monitoring and follow-up care for individuals with ABCA1 mutations are essential to assess lipid levels, cardiovascular risk factors, and disease progression. Close monitoring allows for early detection of complications such as atherosclerosis, coronary artery disease, diabetes, enabling timely intervention and management strategies to optimize cardiovascular health and prevent adverse outcomes.

Strategies for coping with the challenges associated with ABCA1 mutations

Coping with the challenges associated with ABCA1 mutations involves fostering a supportive network, and seeking genetic counseling for a comprehensive understanding of the condition.  Additionally, staying informed about diet and lifestyle modifications to optimize cholesterol levels is essential. 

Engaging in regular communication with healthcare providers can help address concerns, navigate treatment decisions, and access appropriate support services to manage the physical and emotional aspects of living with ABCA1-related disorders.

What's 
ABCA1
?
If Your Levels Are High
Symptoms of High Levels
If Your Levels are Low
Symptoms of Low Levels

Hey Practitioners! Ready to become a world class gut health expert? Join Jeannie Gorman, MS, CCN, for a Free Live Class that dives into how popular diets impact the gut microbiome, the clinical dietary needs of your gut, biomarkers to test to analyze gut health, and gain a clear understanding of the Doctor’s Data GI360™ profile. Register here.

See References

[1.] ABCA1 ATP binding cassette subfamily A member 1 [Homo sapiens (human)] - Gene - NCBI. Nih.gov. Published 2020. https://www.ncbi.nlm.nih.gov/gene/19

[2.] Barbosa-Gouveia S, Fernández-Crespo S, Lazaré-Iglesias H, González-Quintela A, Vázquez-Agra N, Hermida-Ameijeiras Á. Association of a Novel Homozygous Variant in ABCA1 Gene with Tangier Disease. J Clin Med. 2023 Mar 30;12(7):2596. doi: 10.3390/jcm12072596. PMID: 37048678; PMCID: PMC10094818.

[3.] Brunham LR, Kang MH, Van Karnebeek C, Sadananda SN, Collins JA, Zhang LH, Sayson B, Miao F, Stockler S, Frohlich J, Cassiman D, Rabkin SW, Hayden MR. Clinical, Biochemical, and Molecular Characterization of Novel Mutations in ABCA1 in Families with Tangier Disease. JIMD Rep. 2015;18:51-62. doi: 10.1007/8904_2014_348. Epub 2014 Oct 12. PMID: 25308558; PMCID: PMC4361929. 

[4.] Clee SM, Zwinderman AH, Engert JC, et al. Common Genetic Variation in ABCA1 Is Associated With Altered Lipoprotein Levels and a Modified Risk for Coronary Artery Disease. Circulation. 2001;103(9):1198-1205. doi:https://doi.org/10.1161/01.cir.103.9.1198 

[5.] Ferro Y, Mazza E, Salvati M, Santariga E, Giampà S, Spagnuolo R, Doldo P, Pujia R, Coppola A, Gazzaruso C, Pujia A, Montalcini T. Effects of a Portfolio-Mediterranean Diet and a Mediterranean Diet with or without a Sterol-Enriched Yogurt in Individuals with Hypercholesterolemia. Endocrinol Metab (Seoul). 2020 Jun;35(2):298-307. doi: 10.3803/EnM.2020.35.2.298. Epub 2020 Jun 24. PMID: 32615714; PMCID: PMC7386117.

[6.] Franczyk B, Gluba-Brzózka A, Ciałkowska-Rysz A, Ławiński J, Rysz J. The Impact of Aerobic Exercise on HDL Quantity and Quality: A Narrative Review. Int J Mol Sci. 2023 Feb 28;24(5):4653. doi: 10.3390/ijms24054653. PMID: 36902082; PMCID: PMC10003711.

[7.] Lira, F.S., Yamashita, A.S., Uchida, M.C. et al. Low and moderate, rather than high intensity strength exercise induces benefit regarding plasma lipid profile. Diabetol Metab Syndr 2, 31 (2010). https://doi.org/10.1186/1758-5996-2-31

[8.] Wang J, Xiao Q, Wang L, Wang Y, Wang D, Ding H. Role of ABCA1 in Cardiovascular Disease. J Pers Med. 2022 Jun 20;12(6):1010. doi: 10.3390/jpm12061010. PMID: 35743794; PMCID: PMC9225161.

[9.] Yanai H, Tada N. Which Nutritional Factors Are Good for HDL? J Clin Med Res. 2018 Dec;10(12):936-939. doi: 10.14740/jocmr3646. Epub 2018 Oct 30. PMID: 30425767; PMCID: PMC6225857. 

Test for

ABCA1

Order, track, and receive results from 30+ labs in one place.